The ten commandments of chemoembolization: Expert discussion and report from Mediterranean Interventional Oncology (MIOLive) congress 2017

K. Malagari, R. Iezzi, S. N. Goldberg, J. I. Bilbao, A. Sami, O. Akhan, F. Giuliante, M. Pompili, L. Crocetti, V. Valentini, A. Gasbarrini, C. Colosimo, R. Manfredi

Research output: Contribution to journalArticle

Abstract

Transarterial therapies in the setting of primary and secondary liver malignancies are becoming an essential part of the oncology landscape. The mechanism of action of c-TACE is the induction of tumor necrosis due to the high concentration of the chemotherapeutic that is delivered only locally and to the embolic effect that causes ischemia and increased dwell time of the chemotherapeutic in the tumor. Recently, DEB-TACE has emerged as a variation of c-TACE with the potential for the selective delivery of large amounts of drugs to the tumor for a prolonged period, thereby decreasing plasma levels of the chemotherapeutic agent and related systemic effects. There is an increasing consensus that compared with conventional lipiodol-based regimen, DEB-TACE offers standardized methodology, is more reproducible and is associated with improved response and significantly better safety profile. Using an easy to access point by point format, this manuscript summarizes the expert discussion from the Mediterranean Interventional Oncology Live Congress (MIOLive 2017) about the role of TACE in the treatment of liver tumors.

Original languageEnglish
Pages (from-to)372-381
Number of pages10
JournalEuropean Review for Medical and Pharmacological Sciences
Volume22
Issue number2
Publication statusPublished - Jan 1 2018

Fingerprint

Neoplasms
Ethiodized Oil
Liver
Necrosis
Ischemia
Safety
Pharmaceutical Preparations
Therapeutics

Keywords

  • Beads
  • Chemoembolization
  • HCC
  • Lipiodol
  • Liver
  • Locoregional treatment

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

@article{05aaa4be7fff438d9b9e4f3d97261f76,
title = "The ten commandments of chemoembolization: Expert discussion and report from Mediterranean Interventional Oncology (MIOLive) congress 2017",
abstract = "Transarterial therapies in the setting of primary and secondary liver malignancies are becoming an essential part of the oncology landscape. The mechanism of action of c-TACE is the induction of tumor necrosis due to the high concentration of the chemotherapeutic that is delivered only locally and to the embolic effect that causes ischemia and increased dwell time of the chemotherapeutic in the tumor. Recently, DEB-TACE has emerged as a variation of c-TACE with the potential for the selective delivery of large amounts of drugs to the tumor for a prolonged period, thereby decreasing plasma levels of the chemotherapeutic agent and related systemic effects. There is an increasing consensus that compared with conventional lipiodol-based regimen, DEB-TACE offers standardized methodology, is more reproducible and is associated with improved response and significantly better safety profile. Using an easy to access point by point format, this manuscript summarizes the expert discussion from the Mediterranean Interventional Oncology Live Congress (MIOLive 2017) about the role of TACE in the treatment of liver tumors.",
keywords = "Beads, Chemoembolization, HCC, Lipiodol, Liver, Locoregional treatment",
author = "K. Malagari and R. Iezzi and Goldberg, {S. N.} and Bilbao, {J. I.} and A. Sami and O. Akhan and F. Giuliante and M. Pompili and L. Crocetti and V. Valentini and A. Gasbarrini and C. Colosimo and R. Manfredi",
year = "2018",
month = "1",
day = "1",
language = "English",
volume = "22",
pages = "372--381",
journal = "European Review for Medical and Pharmacological Sciences",
issn = "1128-3602",
publisher = "Verduci Editore",
number = "2",

}

TY - JOUR

T1 - The ten commandments of chemoembolization

T2 - Expert discussion and report from Mediterranean Interventional Oncology (MIOLive) congress 2017

AU - Malagari, K.

AU - Iezzi, R.

AU - Goldberg, S. N.

AU - Bilbao, J. I.

AU - Sami, A.

AU - Akhan, O.

AU - Giuliante, F.

AU - Pompili, M.

AU - Crocetti, L.

AU - Valentini, V.

AU - Gasbarrini, A.

AU - Colosimo, C.

AU - Manfredi, R.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Transarterial therapies in the setting of primary and secondary liver malignancies are becoming an essential part of the oncology landscape. The mechanism of action of c-TACE is the induction of tumor necrosis due to the high concentration of the chemotherapeutic that is delivered only locally and to the embolic effect that causes ischemia and increased dwell time of the chemotherapeutic in the tumor. Recently, DEB-TACE has emerged as a variation of c-TACE with the potential for the selective delivery of large amounts of drugs to the tumor for a prolonged period, thereby decreasing plasma levels of the chemotherapeutic agent and related systemic effects. There is an increasing consensus that compared with conventional lipiodol-based regimen, DEB-TACE offers standardized methodology, is more reproducible and is associated with improved response and significantly better safety profile. Using an easy to access point by point format, this manuscript summarizes the expert discussion from the Mediterranean Interventional Oncology Live Congress (MIOLive 2017) about the role of TACE in the treatment of liver tumors.

AB - Transarterial therapies in the setting of primary and secondary liver malignancies are becoming an essential part of the oncology landscape. The mechanism of action of c-TACE is the induction of tumor necrosis due to the high concentration of the chemotherapeutic that is delivered only locally and to the embolic effect that causes ischemia and increased dwell time of the chemotherapeutic in the tumor. Recently, DEB-TACE has emerged as a variation of c-TACE with the potential for the selective delivery of large amounts of drugs to the tumor for a prolonged period, thereby decreasing plasma levels of the chemotherapeutic agent and related systemic effects. There is an increasing consensus that compared with conventional lipiodol-based regimen, DEB-TACE offers standardized methodology, is more reproducible and is associated with improved response and significantly better safety profile. Using an easy to access point by point format, this manuscript summarizes the expert discussion from the Mediterranean Interventional Oncology Live Congress (MIOLive 2017) about the role of TACE in the treatment of liver tumors.

KW - Beads

KW - Chemoembolization

KW - HCC

KW - Lipiodol

KW - Liver

KW - Locoregional treatment

UR - http://www.scopus.com/inward/record.url?scp=85041425265&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85041425265&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:85041425265

VL - 22

SP - 372

EP - 381

JO - European Review for Medical and Pharmacological Sciences

JF - European Review for Medical and Pharmacological Sciences

SN - 1128-3602

IS - 2

ER -